1 bottle (vial) with powder for preparation of solution for parenteral use of the drug Longidasa contains:
Conjugate of hyaluronidase with copolymer (N-oxide 1,4-ethylenebased and (N-carboxymethyl)-1,4-ethyleneimine bromide) – 1500 IU or 3000 IU;
For more substance.
Longidasa – conjugate proteolytic enzyme hyaluronidase with high molecular carrier substance of the group of derivatives of N-oxide poly-1,4-etilenpiperazina. Longidasa has pharmacological properties inherent in drugs with hyaluronidase activity. In particular, the drug Logidata has a strong decongestant, antioxidant, anti-inflammatory, helatiruyushchey and immunomodulatory effects.
Specific substrates of hyaluronidase are glycosaminoglycans (specifically chondroitin, hyaluronic acid, chondroitin-6-sulfate and chondroitin-4-sulfate) – substance of connective tissue. As a result of glycolysis there is a decrease in viscosity of glycosaminoglycans, the ability to bind metal ions and water, thus increasing the permeability and trophic tissues, reduces the severity of swelling and bruising, increases the elasticity of the cicatricial areas, and also avoids adhesions and contractures and improves joint mobility. The most pronounced effect of the drug Longidasa gives in the initial stages of the pathological process.
The effectiveness of the drug Longidasa significantly exceeds that of the native hyaluronidase, as the conjugation contributes to the stability of the enzyme to the action of temperature and inhibitory substances.
The antioxidant action of the drug Longidasa due to the ability of active substances to bind released iron ions, which activates free-radical reactions, stimulators of the synthesis of collagen and inhibitors of hyaluronidase. Polytropic properties of the drug are implemented in protivopoloznom action, which is a proven biochemical, electron microscopic and histological studies in a model of pulmonary fibrosis.
Longidasa regulates the synthesis of mediators of inflammation, weakens during the acute phase of the inflammatory process, stimulates humoral immunity and increases the body's resistance to infections.
The drug does not worsen the postoperative period, causes the progression of the infectious process, has no negative effect on the recovery of bone tissue. These properties allow to apply the drug Logidata as a means of prevention of rough scarring and adhesions after surgery.
During simultaneous parenteral administration of the drug Longidasa enhances absorption of other drugs and accelerates the action of local anesthetics.
Longidasa low toxic drug, without affecting the normal function of the immune and reproductive system. Longidasa has no mutagenic, carcinogenic and teratogenic effects.
For parenteral use of the drug Longidasa the active ingredient is rapidly absorbed into the systemic circulation, reaching peak values in plasma for 20-25 minutes. The half-life of the active ingredient when administered intramuscularly up to 36 hours following subcutaneous injection 45 hours. The bioavailability of the drug when administered parenterally up to 90%.
The active component of the drug penetrates through Longidasa gematoplatzentarnyi, brain and ocular barriers.
Hyaluronidase gidrolizuyutza in the body, the carrier breaks up the oligomers and excreted by the kidneys in two phases. Fully Longidasa the drug is eliminated from the body within 4-5 hours after injecting.
Indications for use
Powder for preparation of solution for parenteral use Longidasa used in the treatment of patients suffering from diseases accompanied by hyperplasia of the connective tissue. In particular, the drug Longidasa used:
In gynecological practice in the adhesions in the pelvis, which accompany inflammatory diseases of internal genital organs (including intrauterine adhesions, tubal-peritoneal infertility and chronic form of endometritis).
In urological practice in chronic prostatitis and interstitial cystitis.
In surgical practice at adhesive process after surgical interventions on the abdominal cavity, hypertrophic scarring after burns, injuries, operations, pyoderma, and nonhealing wounds.
In dermatological and cosmetological practice with limited scleroderma, emerging, keloid and hypertrophic scars after pyoderma, operations, injuries and burns.
In the practice of pulmonology and tuberculosis with the pulmonary fibrosis, cavernous fibrous or infiltrative tuberculosis, tuberculoma, fibroporous alveolitis.
In orthopedics, with the contracture of the joints, ankylosing spondylitis, arthritis and bruises.
Also the drug Longidasa can be used to improve the bioavailability of antimicrobials and local anesthetics in the urological, gynecological, pulmonary and dermatological practice.
Drug Longidasa by the decision of the doctor may be appointed as the prevention of scarring and strictures after surgical interventions.
Method of application
Powder Longidasa designed for preparation of solution for parenteral use. The ready solution is designed to be injected intramuscularly, subcutaneously and intradermally. Banned intravenous solution Longidasa. Subcutaneously, as a rule, the solution is administered close to the place of defeat or under the scar tissue.
To prepare the solution into the vial add 1.0-2.0 ml 0.25-0.5% solution of procaine (procaine intolerance should be replaced with 0.9% sodium chloride solution or water for injection). In preparing the solution for increasing the bioavailability of drugs, the vial contents will dissolve in 2 ml (3000 IU) or 1 ml (1500 IU) solution of sodium chloride isotonic. The solvent must enter it into the bottle slowly, after a few minutes the solution was carefully stirred, shaking (rapid introduction of a solvent or shaking the bottle can cause foaming of the protein). The resulting solution is used immediately, store the diluted solution is prohibited.
The duration of therapy and drug doses Longidasa determined by the physician.
In the prevention the formation of adhesions and scarring after surgery is usually prescribed the introduction of 3,000 IU of the drug Longidasa 1 time in 72 hours. The total course dose is 5 injections. Depending on the risk of developing adhesions dose may be increased to 10 injections (in this case, the injection should be carried out with an interval of 5 days).
In gynecological practice in the adhesive process usually prescribed 3,000 IU of the drug Logidata intramuscularly every 3-5 days. The total course dose is 10-15 injections.
In gynecological practice in the tubal-peritoneal infertility is usually prescribed 3,000 IU of the drug Logidata intramuscularly every 3 days, after 5 injections, the interval between injections increased to 5 days. The total course dose of 15 injections.
In urological practice in chronic prostatitis and interstitial cystitis usually prescribed 3,000 IU of the drug Logidata intramuscularly 1 time per 5 days. The total course dose is 10-15 injections.
In surgical practice for adhesive disease after surgical interventions usually prescribed 3,000 IU of the drug Logidata intramuscularly 1 time in 3-5 days. The total course dose is 10-15 injections.
In surgical practice in nonhealing wounds is usually prescribed 3,000 IU of the drug Logidata intramuscularly 1 time per 5 days. The total course dose is 5-10 injections.
In dermatological and cosmetological practice with limited scleroderma usually 3000-4500 IU of the drug Logidata intramuscularly 1 time in 3-5 days. The total course dose is up to 20 injections.
In dermatological and cosmetological practice in keloid formed and hypertrophic scars after burns, pyoderma and wounds usually 3000-4500 IU of drug subcutaneously or Longidasa vnutrisustavno 1 time in 3 days. The total course dose is up to 15 injections. The rate may be increased to 25 injections with a mandatory increase in the interval between injections to 5 days. By the decision of the doctor alternate vnutrisustavno and intramuscular administration of the drug Logidata.
In the practice of pulmonology and Phthisiology usually prescribed 3,000 IU of the drug Logidata intramuscularly 1 time per 5 days. The total course dose in pulmonary fibrosis is 10 injections, with fibroporous alveolitis – 15 injections, with further supportive therapy (1 infusion in 10 days for a course of up to 25 injections), TB – 25 injection (with a possible extension of therapy to 6-12 months with the introduction of 3,000 IU of the drug Longidasa 1 every 10 days).
In orthopaedic practice in contracture of the joints, bruises, arthritis and ankylosing spondylosis is usually prescribed 3,000 IU of the drug Longidasa subcutaneously near the site of the damage 1 every 3 days. The total course dose of 5-15 injections. If necessary, therapy is prolonged, increasing the interval between injections to 5 days.
To increase bioavailability of drugs 1500 IU of the drug Longidasa administered 10-15 minutes before introducing the main product at the same location as the main drug.
Prohibited the introduction of the drug Longidasa in areas with acute infectious inflammation.
If you skip doses it should be administered as early as possible, but should not double the dose of the drug Logidata.
In severe chronic productive process in the connective tissue after a standard course of therapy is prescribed long-term maintenance therapy (3000 IU of preparation Longidase 1 every 10-14 days).
Patients with renal insufficiency should not be prescribed more than 3000 in a week.
When use of the drug Longidasa patients may develop local or systemic allergic reactions. When applying the solution for injection Longidasa patients also may develop local reactions in the form of soreness at the injection site, redness, itching and swelling at the injection site. Local reactions generally did not require discontinuation of the drug and pass on their own in 24-72 hours.
Drug Longidasa not used for the treatment of patients with a known hypersensitivity to the components of the powder for preparation of solution for injection.
Drug Longidasa not used for the treatment of patients with malignant tumors and severe disorders of the kidneys.
It should appoint a drug Longidasa patients with pulmonary hemorrhage, hemoptysis, severe infectious diseases, and recent hemorrhage into the vitreous body.
The pediatric powder for preparation of solution for injections Longidasa not apply.
With caution should appoint drug Longidasa patients with renal insufficiency, and patients who had recently been bleeding.
Drug Longidasa not used in the treatment of pregnant and lactating women.
If you avoid the drug Longidasa lactation should not stop breast feeding.
Longidasa potentiates the action of antimicrobials, local anesthetics, and diuretics when used in combination.
While the use of high doses of salicylates, cortisone, estrogen, adrenocorticotropic hormone, and antihistamines to reduce the effectiveness of the drug Logidata.
Not recommended simultaneous application of the drug Longidasa with furosemide, phenytoin and benzodiazepines.
When applying excessive doses of the drug Longidasa patients may develop chills, dizziness, fever, and lower blood pressure.
There is no specific antidote. With the development of signs of overdose, discontinue administration of the drug Longidasa and if necessary spend symptomatic therapy.
Powder lyophilized for solution preparation for parenteral use according to Longidasa 15mg (1500 IU of active substance) or 20 mg (3000 IU of active substance) in vials or dark glass bottles, in a carton box 5 ampoules or vials that are nested in contour packaging made of polymeric materials.
Drug Longidasa should be stored in a temperature-controlled environment from 8 to 15 degrees Celsius for not more than 2 years after graduation.
Prepared solution for parenteral use Longidasa is not ready for storage.